Screening antivirals with a mCherry-expressing recombinant bovine respiratory syncytial virus: a proof of concept using cyclopamine.
Bovine respiratory syncytial virus
antiviral drugs
cyclopamine
mCherry reverse genetics
Journal
Veterinary research
ISSN: 1297-9716
Titre abrégé: Vet Res
Pays: England
ID NLM: 9309551
Informations de publication
Date de publication:
17 Apr 2023
17 Apr 2023
Historique:
received:
20
05
2022
accepted:
17
03
2023
medline:
19
4
2023
entrez:
18
4
2023
pubmed:
19
4
2023
Statut:
epublish
Résumé
Bovine respiratory syncytial virus (BRSV) is a pathogenic pneumovirus and a major cause of acute respiratory infections in calves. Although different vaccines are available against BRSV, their efficiency remains limited, and no efficient and large-scale treatment exists. Here, we developed a new reverse genetics system for BRSV expressing the red fluorescent protein mCherry, based on a field strain isolated from a sick calf in Sweden. Although this recombinant fluorescent virus replicated slightly less efficiently compared to the wild type virus, both viruses were shown to be sensitive to the natural steroidal alkaloid cyclopamine, which was previously shown to inhibit human RSV replication. Our data thus point to the potential of this recombinant fluorescent BRSV as a powerful tool in preclinical drug discovery to enable high throughput compound screening.
Identifiants
pubmed: 37069656
doi: 10.1186/s13567-023-01165-x
pii: 10.1186/s13567-023-01165-x
pmc: PMC10111787
doi:
Substances chimiques
cyclopamine
ZH658AJ192
Antiviral Agents
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
36Subventions
Organisme : Agence Nationale de la Recherche
ID : ANR-19-CE11-0017
Organisme : Agence nationale de la recherche
ID : ANR-17-CE20-0018
Organisme : Horizon 2020 Framework Programme
ID : 633184 SAPHIR
Organisme : Svenska Forskningsrådet Formas
ID : 2016-00463
Informations de copyright
© 2023. The Author(s).
Références
Arch Virol. 1999;144(10):1977-90
pubmed: 10550670
J Virol. 2009 Feb;83(4):1962-8
pubmed: 19052091
J Virol. 1999 Jan;73(1):251-9
pubmed: 9847328
BMC Vet Res. 2021 Jul 31;17(1):261
pubmed: 34332574
PLoS Pathog. 2012;8(5):e1002734
pubmed: 22675274
Nat Commun. 2014 Oct 03;5:5104
pubmed: 25277263
Arch Virol. 2016 Aug;161(8):2351-60
pubmed: 27216929
Structure. 2020 Sep 1;28(9):979-990.e4
pubmed: 32697936
J Virol. 1996 Jun;70(6):3478-87
pubmed: 8648680
Nature. 2021 Jul;595(7868):596-599
pubmed: 34234347
Sci Rep. 2016 May 19;6:25806
pubmed: 27194388
Vaccine. 2011 Nov 3;29(47):8719-30
pubmed: 21864616
Vet Res. 2007 Mar-Apr;38(2):153-80
pubmed: 17257568
J Virol. 2002 Dec;76(23):12355-9
pubmed: 12414977
NPJ Vaccines. 2017 Mar 8;2:7
pubmed: 29021918
Vaccines (Basel). 2021 Mar 09;9(3):
pubmed: 33803302
Vet Immunol Immunopathol. 1989 Sep;22(2):145-60
pubmed: 2530685
J Virol. 2009 Jul;83(13):6363-74
pubmed: 19386701
Vet Pathol. 2014 Mar;51(2):427-36
pubmed: 24009269
Virus Genes. 2001;23(2):157-64
pubmed: 11724268
Vet Microbiol. 2017 Jul;206:59-68
pubmed: 28024854
PLoS One. 2022 Sep 16;17(9):e0274332
pubmed: 36112582
J Gen Virol. 2004 Jun;85(Pt 6):1643-1653
pubmed: 15166449